Jagsonpal Pharmaceuticals Limited has entered into a Business Transfer Agreement (BTA) with Group Pharmaceuticals Limited for the acquisition of Group Pharma’s Wellness Portfolio on a going-concern basis through a slump sale. The transaction includes an initial consideration of ₹23.7 crore payable at closing. An additional consideration of up to ₹23 crore will be linked to sales achieved in FY2027-28, subject to a total consideration cap of ₹46.7 crore. The transaction is expected to be completed on or before November 1, 2026, subject to fulfilment of conditions precedent and other terms under the BTA.
The acquisition will add an established portfolio of wellness products and an existing market presence to Jagsonpal’s business. The company plans to integrate the portfolio with its existing commercial platform and use its distribution network to create operating and cross-selling opportunities.
Commenting on the acquisition, Manish Gupta, Managing Director, Jagsonpal Pharmaceuticals, said, “The acquisition marks another meaningful step in our growth journey. It strengthens our pharmaceutical portfolio and expands our presence across complementary therapeutic segments especially in women healthcare, while remaining consistent with our asset-light and focused approach to growth. We remain focused on pursuing opportunities that complement our existing capabilities and create sustainable, long-term value for all our stakeholders.”
Amrut Medhekar, Chief Operating Officer, Jagsonpal, said, “We are delighted to welcome this portfolio and the employees of the business into our organization, and are fully committed to ensuring their smooth and seamless integration. We are equally excited about this acquisition as we embark on our next phase of growth, expanding our field force, strengthening our pan-India presence and creating significant cross-selling opportunities across our portfolio. Together, we look forward to a seamless transition and unlocking the portfolio’s full growth potential by leveraging our established commercial infrastructure and strong execution capabilities.”
The transaction remains subject to applicable conditions precedent and other customary closing conditions specified in the BTA. Think law Advisors represented Jagsonpal as its legal advisor, while Tatva Legal advised Group Pharma on the transaction. Jagsonpal Pharmaceuticals has more than five decades of presence in the Indian pharmaceutical market. The company has a portfolio focused on gynaecology, orthopaedics and dermatology and has developed brands across these segments.
Jagsonpal has more than 20 brands ranked among the top five in their respective molecule categories. The company has a pan-India presence supported by a sales team of more than 1,000 professionals. The company is listed on the National Stock Exchange under the symbol JAGSNPHARM and on the Bombay Stock Exchange under scrip code 507789. Its headquarters are in Delhi.
